➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Boehringer Ingelheim
AstraZeneca
Moodys
Johnson and Johnson

Last Updated: August 3, 2020

DrugPatentWatch Database Preview

RAPAFLO Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Rapaflo patents expire, and when can generic versions of Rapaflo launch?

Rapaflo is a drug marketed by Allergan and is included in one NDA.

The generic ingredient in RAPAFLO is silodosin. There are twelve drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the silodosin profile page.

US ANDA Litigation and Generic Entry Outlook for Rapaflo

A generic version of RAPAFLO was approved as silodosin by SANDOZ INC on March 31st, 2017.

  Start Trial

Drug patent expirations by year for RAPAFLO
Drug Prices for RAPAFLO

See drug prices for RAPAFLO

Drug Sales Revenue Trends for RAPAFLO

See drug sales revenues for RAPAFLO

Recent Clinical Trials for RAPAFLO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Sir Mortimer B. Davis - Jewish General HospitalPhase 3
Albert Einstein Healthcare NetworkPhase 4
Watson PharmaceuticalsPhase 2

See all RAPAFLO clinical trials

Pharmacology for RAPAFLO
Paragraph IV (Patent) Challenges for RAPAFLO
Tradename Dosage Ingredient NDA Submissiondate
RAPAFLO CAPSULE;ORAL silodosin 022206 2012-10-09

US Patents and Regulatory Information for RAPAFLO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan RAPAFLO silodosin CAPSULE;ORAL 022206-001 Oct 8, 2008 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Allergan RAPAFLO silodosin CAPSULE;ORAL 022206-002 Oct 8, 2008 AB RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for RAPAFLO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan RAPAFLO silodosin CAPSULE;ORAL 022206-002 Oct 8, 2008   Start Trial   Start Trial
Allergan RAPAFLO silodosin CAPSULE;ORAL 022206-001 Oct 8, 2008   Start Trial   Start Trial
Allergan RAPAFLO silodosin CAPSULE;ORAL 022206-001 Oct 8, 2008   Start Trial   Start Trial
Allergan RAPAFLO silodosin CAPSULE;ORAL 022206-001 Oct 8, 2008   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for RAPAFLO

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0600675 SPC/GB10/031 United Kingdom   Start Trial PRODUCT NAME: SILODOSIN, OPTIONALLY IN A FORM OF A PHARMACEUTICAL ACCEPTABLE SALT; REGISTERED: UK EU/1/09/607/001-014 20100129; UK EU/1/09/608/001-014 20100129
0600675 1090028-0.L Sweden   Start Trial PRODUCT NAME: SILODOSIN ELLER FARMACEUTISKA GODTAGBARA SALTER DAERAV; REG. NO/DATE: EU/1/09/607/001-014 " EESGODKLANDKOD="EG" EESGODKDATUM="2010-01-29" SEGODKNR="EU/1/09/607/001-014 " SEGODKLANDKOD="EG" SEGODKDATUM="2010-01-29" FLAG="L" SPCNR="1090028-0" 20100129
0600675 10C0036 France   Start Trial PRODUCT NAME: SILODOSIN; REGISTRATION NO/DATE IN FRANCE: EU/1/09/608/001 DU 20100129; REGISTRATION NO/DATE AT EEC: EU/1/09/608/001 DU 20100129
0600675 C300454 Netherlands   Start Trial PRODUCT NAME: SILODOSIN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/09/607/001-014EU/1/09/608/001-014 2010290129
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Express Scripts
AstraZeneca
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.